Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due to ...
Investigational BAY 2927088 is an oral, small molecule, tyrosine kinase inhibitor as a potential new targeted therapy for patients with non-small cell lung cancer (NSCLC) harboring HER2 activating ...
The FDA on Friday granted accelerated approval to zongertinib (Hernexeos) for non-squamous non-small cell lung cancer (NSCLC) patients harboring HER2 tyrosine kinase domain (TKD) activating mutations.
NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...
RYZ101 (225Ac-DOTATATE) in patients with estrogen receptor-positive, human epidermal growth factor receptor 2–negative, locally advanced and unresectable, or metastatic breast cancer progressing after ...
Many people are familiar with histamine, a biological molecule, that serves as a key driver of allergic reactions and other immune responses. However ...
Many people are familiar with histamine, a biological molecule that serves as a key driver of allergic reactions and other ...
Sevabertinib shows promise for advanced NSCLC with HER2 mutations, achieving a 72.1% objective response rate in the SOHO-01 trial. Patients with HER2 YVMA insertions exhibited a 90% objective response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback